Antibody response to hepatitis B vaccine in substance use disorder patients

[Guest guest]

http://www.drugandalcoholdependence.com/article/PIIS0376871609003561/abstract?rs\

s=yes

DRUG AND ALCOHOL DEPENDENCE

Volume 107, Issue 1, Pages 39-43 (1 February 2010)

Antibody response to hepatitis B vaccine in substance use disorder patients

Hildi J. Hagedornabc, A. Rettmanna, W. Dieperinkbc, Janet Durfeed,

Bashar Aqele

Received 20 May 2009; received in revised form 1 September 2009; accepted 3

September 2009.

Abstract

The objectives of this study were to assess the prevalence of prognostic factors

previously known to be associated with poor antibody response to hepatitis B

vaccination in a sample of veterans presenting for substance use disorders

treatment at a Veterans Health Administration (VA) Medical Center, assess

vaccination response, and identify markers for poor response in this population.

Results indicated that most participants had multiple prognostic factors

previously known to be associated with poor antibody response including male

gender, age over 40, smoking, and obesity. The rate of seroconversion in this

sample was 51.9%. This is substantially lower than seen in healthy adults.

Alcohol dependence was the only significant independent negative predictor of

seroconversion in this sample. Substance use disorders treatment providers who

are considering adding hepatitis B vaccination services to their clinics should

be aware that the antibody response to the hepatitis B vaccination is

inconsistent and that patients with particular demographic characteristics may

be at heightened risk of poor antibody response.

a Veterans Health Administration's Substance Use Disorders Quality Enhancement

Research Initiative, Minneapolis VA Medical Center, Minneapolis, MN 55417, USA

b University of Minnesota School of Medicine, Department of Psychiatry,

Minneapolis, MN 55455, USA

c Veterans Health Administration's Hepatitis C Resource Center, Minneapolis VA

Medical Center, Minneapolis, MN 55417, USA

d Public Health Strategic Healthcare Group, Department of Veterans Affairs,

Washington, DC 20420, USA

e Mayo Clinic College of Medicine, Division of Transplant Medicine,

Gastroenterology and Hepatology, Phoenix, AZ 85054, USA

Corresponding author at: Minneapolis VA Medical Center, One Veterans Drive,

116A9, Minneapolis, MN 55417, USA. Tel.: +1 612 467 3875; fax: +1 612 467 5265.

PII: S0376-8716(09)00356-1

doi:10.1016/j.drugalcdep.2009.09.004

Published by Elsevier Inc.